ArticleFrontiers in oncology2024

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience.

Ningning Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.